The biology of ovarian cancer: new opportunities for translation (original) (raw)

• Goff, B. A. et al. Ovarian carcinoma diagnosis. Cancer 89, 2068 (2000).
  Article CAS PubMed Google Scholar
• Zebrowski, B. K. et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol. 6, 373 (1999).
  Article CAS PubMed Google Scholar
• Mesiano, S., Ferrara, N. & Jaffe, R. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Path. 153, 1249 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Numnum, T. M. et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian cancer. Gynecol. Oncol. 102, 425 (2006).
  Article CAS PubMed Google Scholar
• Berek, J. S. in Practical Gynecologic Oncology 4th edn Ch. 11 Ovarian Cancer (eds Berek, J. S. & Hacker, N. F.) 443–511 (Lippincott Williams & Wilkins, Philadelphia, 2005).
  Google Scholar
• Armstrong, D. K. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34–43 (2006).
  Article CAS PubMed Google Scholar
• Feeley, K. M. & Wells, M. Precursor lesions of ovarian epithelial malignancy. Histopathology 38, 87 (2001).
  Article CAS PubMed Google Scholar
• Zhang, S. et al. Identification and characterization of ovarian cancer initiating cells from primary human tumors. Cancer Res. 68, 4311–4320 (2008). This report established the phenotype of tumour-initiating ovarian cancer cells.
  Article CAS PubMed PubMed Central Google Scholar
• Alvero, A. B. et al. Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemoresistance. Cell Cycle 8, 188–169 (2009).
  Article Google Scholar
• Jacobs, I. J. et al. Clonal origin of epithelial ovarian cancer: analysis by loss of heterozygosity, p53 mutation and X chromosome inactivation. J. Natl Cancer Inst. 84, 1793–1798 (1992).
  Article CAS PubMed Google Scholar
• Bast, R. C. Jr & Mills, G. B. in The Molecular Basis of Cancer 3rd edn (eds Mendelsohn, J., Howley, P., Israel, M., Gray, J. & Thompson, C. ) 441–455 (W. B. Saunders Co., Philadelphia, 2008).
  Book Google Scholar
• Iwabuchi, H. et al. Genetic analysis of benign, low-grade and high-grade ovarian tumors. Cancer Res. 55, 6172–6180 (1995).
  CAS PubMed Google Scholar
• Risch, H. A. et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl Cancer Inst. 98, 1675–1677 (2006).
  Article CAS Google Scholar
• Cramer, D. W. et al. Genital talc exposure and risk of ovarian cancer. Int. J. Cancer 81, 351–356 (1999).
  Article CAS PubMed Google Scholar
• Muscat, J. E. & Huncharek, M. S. Perineal talc use and ovarian cancer: a critical review. Eur. J. Cancer Prev. 62, 358–360 (2006).
  Google Scholar
• Kohler, M. F. et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl Cancer Inst. 85, 1513–1519 (1993). This paper indicated that ovarian cancers undergo spontaneous mutation.
  Article CAS PubMed Google Scholar
• Berchuck, A. et al. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol. Oncol. 52, 232–236 (1994).
  Article CAS PubMed Google Scholar
• Berchuck, A. et al. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol. 170, 246–252 (1994).
  Article CAS PubMed Google Scholar
• Havrilesky, L. et al., Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3814–3825 (2003).
  Article CAS PubMed Google Scholar
• Hall, J. et al. Critical evaluation of p53 as a prognostic marker in ovarian cancer. Exp. Rev. Mol. Med. 12, 1–20 (2004). A thoughtful and thorough review of the prognostic significance of p53 in ovarian cancer.
  Article Google Scholar
• Buller, R. E. et al. A phase I/II trial of rAd/p53 (SCH58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9, 553–566 (2002).
  Article CAS PubMed Google Scholar
• Vasey, P. A. et al. Phase I trial of intraperitoneal injection of the _E1B_-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 15, 1562–1569 (2002).
  Google Scholar
• Kojima, K. et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106, 3150–3159 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, Y. et al. in Methods in Enzymology: Regulators and Effectors of Small GTPases. Ras Proteins Vol. 407 (eds Balch, W. E., Der, C. & Hall, A.) 455–467 (Academic, New York, 2006). A comprehensive review of the role of DIRAS3 (ARHI) in ovarian cancer.
  Book Google Scholar
• Cvetkovic, D. et al. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. Gynecol. Oncol. 95, 449–455 (2004).
  Article CAS PubMed Google Scholar
• Feng, W. et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112, 1489–1502 (2008).
  Article CAS PubMed Google Scholar
• Chen, M. Y. et al. Synergistic inhibition of ovarian cancer cell growth with demethylating agents and histone deacetylase inhibitors. Proc. Amer. Assoc. Cancer Res. 681 (2007).
• Mackay, H. et al. A phase II trial of the histone deacetylase inhibitor belinostat (PSC101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial. J. Clin. Oncol. 26 (Suppl.) 5518 (2008).
  Article Google Scholar
• Balch, C. et al. The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet. Gynecol. 191, 1552–1572 (2004).
  Article CAS PubMed Google Scholar
• Bast, R. C. et al. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer. J. Clin. Oncol. 26 (Suppl.) 3500 (2008).
  Article Google Scholar
• Rubin, S. C. et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am. J. Obstet. Gynecol. 178, 670–677 (1998).
  Article CAS PubMed Google Scholar
• Lancaster, J. M. et al. BRCA2 mutations in primary breast and ovarian cancers. Nature Genet. 13, 238–240 (1996).
  Article CAS PubMed Google Scholar
• Boyd, J. in Ovarian Cancer 5 (eds Sharp, F., Blackett, T., Berek, J. & Bast, R.) 3–16 (Isis Medical Media, Oxford, 1998).
  Google Scholar
• Chetrit, A., Hirsh-Yechezkel, G., Ben-David, Y., Lubin, F. & Friedman, E. Effect of BRCA 1/2 mutations on long-term survival of patients with ovarian cancer: the national Israeli study of ovarian cancer. J. Clin. Oncol. 26, 20–25 (2008).
  Article PubMed Google Scholar
• Moynahan, M. E. et al. Homology directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61, 4842–4850 (2001).
  CAS PubMed Google Scholar
• Narod, S. A & Foulkes, W. D. BRCA1 and BRCA2, 1994 and beyond. Nature Rev. Cancer 4, 665–676 (2004).
  Article CAS Google Scholar
• Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111–1115 (2008).
  Article CAS PubMed Google Scholar
• Sakai, W. et al. Secondary mutations as a mechanism of resistance to cisplatin in _BRCA2_-mutated cancers. Nature 451, 1116–1120 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Drew, Y. & Calvert, H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann. NY Acad. Sci. 1138, 126–145 (2008).
  Article CAS Google Scholar
• Yap, T. A., Carden, C. T. & Kaye, S. B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Rev. Cancer 9, 167–181 (2009). A thorough and up-to-date review of molecular therapeutics for ovarian cancer.
  Article CAS Google Scholar
• Hennessey, B. et al. BRCA status in ovarian cancer. Proc. Amer. Soc. Clin. Oncol. (in the press).
• Umayahara, K. et al. in Ovarian Cancer 5 (eds Sharp, F., Blackett, T., Berek, J. & Bast, R.) 17–23 (Isis Medical Media, Oxford, 1998).
  Google Scholar
• Jazaeri, A. A. et al. Gene expression profiles of _BRCA1_-linked, _BRCA2_-linked, and sporadic ovarian cancers. J. Natl Cancer Inst. 13, 990–1000 (2002). This provocative paper suggests that sporadic ovarian cancers are either BRCA1 or BRCA2-like.
  Article Google Scholar
• Eder, A. M. et al. Atypical PKCι contributes to poor prognosis through loss of apical–basal polarity and cyclin E overexpression in ovarian cancer. Proc. Natl Acad. USA 102, 12519–12524 (2005).
  Article CAS Google Scholar
• Zhang, L. et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl Acad. Sci. USA 103, 9136–9141 (2003).
  Article CAS Google Scholar
• Tangir, J. et al. Frequent microsatellite instability in epithelial borderline ovarian tumors. Cancer Res. 56, 2501–2505 (1996).
  CAS PubMed Google Scholar
• Rodabaugh, K. J. et al. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene 11, 1249–1254 (1995).
  CAS PubMed Google Scholar
• Berchuck, A. et al. Overexpression of p53 is not a feature of benign and early- stage borderline epithelial ovarian tumors. Gynecol. Oncol. 52, 232–236 (1994).
  Article CAS PubMed Google Scholar
• Iwabuchi, H. et al. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res. 55, 6172–6180 (1995).
  CAS PubMed Google Scholar
• Abu-Jawdeh, G. M. et al. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol. Oncol. 60, 301–307 (1996).
  Article CAS PubMed Google Scholar
• Liu, J. et al. A genetically defined model for human ovarian cancer. Cancer Res. 64, 1655–1663 (2004). This paper showed that an ovarian phenotype can be induced in xenografts by transfecting normal human ovarian surface epithelial cells with SV40 T antigen, telomerase and mutant Ras.
  Article CAS PubMed Google Scholar
• Cheng, K. W. et al. Emerging role of Rab GTPases in cancer and human disease. Cancer Res. 65, 2516–2519 (2005).
  Article CAS PubMed Google Scholar
• Gautschi, O. et al. Aurora kinases as cancer drug targets. Clin. Cancer Res. 14, 1639–1648 (2008).
  Article CAS PubMed Google Scholar
• Li, K. et al. Modulation of Notch signaling by antibodies specific for the extracellular regulatory region of Notch3. J. Biol. Chem. 283, 8046–8054 (2008).
  Article CAS PubMed Google Scholar
• Schilder, R. J, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 11, 5539–5548 (2005).
  Article CAS PubMed Google Scholar
• Gordon, A. N. et al. Efficacy and safety of erlotinib HCI, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int. J. Gynecol. Cancer 15, 785–792 (2005).
  Article CAS PubMed Google Scholar
• Heinemann, V., Stintzing, S., Kirchner, T., Boeck, S. & Jung, A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat. Rev. 35, 262–271 (2009).
  Article CAS PubMed Google Scholar
• Bookman, M. A. et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21, 283–290 (2003).
  Article CAS PubMed Google Scholar
• Hu, L., Hofmann, J., Lu, Y., Mills, G. B. & Jaffe, R. B. Inhibition of phophatidylinositol 3′ kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62, 1087–1092 (2002).
  CAS PubMed Google Scholar
• Raynaud, F. L. et al. Pharmacologic characterization of a potent inhibitor of class I phophatidylinositide 3-kinases. Cancer Res. 67, 5840–5850 (2007).
  Article CAS PubMed Google Scholar
• Rosen, D. G. et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107, 2730–2740 (2006).
  Article CAS PubMed Google Scholar
• Burke, W. M. et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20, 7925–7934 (2001).
  Article CAS PubMed Google Scholar
• Duan, Z. et al. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6, 7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol. Pharmacol. 72, 1137–1145 (2007).
  Article CAS PubMed Google Scholar
• McMurray, J. S. A new small molecule Stat 3 inhibitor. Chem. Biol. 13, 1123–1124 (2006).
  Article CAS PubMed Google Scholar
• Murph, M. et al. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin. Cancer Res. 12, 6598–6602 (2006).
  Article CAS PubMed Google Scholar
• Beck, H. P. et al. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg. Med. Chem. Lett. 18, 1037–1041 (2008).
  Article CAS PubMed Google Scholar
• Lin, Y. G. et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clin. Cancer Res. 13, 3423–3430 (2007).
  Article CAS PubMed Google Scholar
• Samanta, A. K, Huang, H. J, Bast, R. C. Jr & Liao, W. Overexpression of MEKK3 confers resistance to apoptosis through activation of NFκB. J. Biol. Chem. 279, 7576–7583 (2004).
  Article CAS PubMed Google Scholar
• Häcker, H. & Karin, M. Regulation and function of IKK and IKK-related kinases. Science STKE 357, re 13 (2006).
  Google Scholar
• Yang, J. et al. The essential role of MEKK3 in TNF-induced NF-κB activation. Nature Immunol. 2, 620–624 (2001).
  Article CAS Google Scholar
• Karin, M. Nuclear factor κB in cancer development and progression. Nature 441, 431–436 (2006).
  Article CAS PubMed Google Scholar
• See, H. T., Kavanagh, J. J., Hu, W. & Bast, R. C. Jr. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int. J. Gynecol. Cancer 13, 701–734 (2004).
  Article Google Scholar
• Suh, D. S., Yoon, M. S., Choi, K. U. & Kim, J. Y. Significance of E2F-1 overexpression in ovarian cancer. Int. J. Gynecol. Cancer 18, 492–498 (2008).
  Article CAS PubMed Google Scholar
• Reimer, D. et al. Expression of the E2 family of transcription factors and its clinical relevance in ovarian cancer. Ann. NY Acad. Sci. 1091, 270–286 (2006).
  Article CAS PubMed Google Scholar
• Berchuck, A. et al. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β. Am. J. Obstet. Gynecol. 166, 676–684 (1992).
  Article CAS PubMed Google Scholar
• Sunde, J. S. et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-β signaling in ovarian cancer. Cancer Res. 66, 8404–8412 (2006).
  Article CAS PubMed Google Scholar
• Fuller, A. F. Jr, Guy, S., Budzik, G. P. & Donahoe, P. K. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line. J. Clin. Endocrinol. Metabol. 54, 1051–1055 (1982).
  Article CAS Google Scholar
• Szotek, P. P. et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc. Natl Acad. Sci. USA 103, 11154–11159 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Pieretti-Vanmarcke, R. et al. Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc. Natl Acad. Sci. USA 103, 17426–17431 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Reed, J. et al. Significance of Fas receptor protein expression in epithelial ovarian cancer. Hum. Pathol. 36, 971–976 (2005).
  Article CAS PubMed Google Scholar
• Kar, R. et al. Role of apoptotic regulators in human epithelial ovarian cancer. Cancer Biol. Ther. 6, 1101–1105 (2007).
  Article CAS PubMed Google Scholar
• Schuyer, M. et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br. J. Cancer 85, 1359–1367 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Lancaster, J. M. et al. High expression of tumor necrosis factor apoptosis- inducing ligand is associated with favorable ovarian cancer survival. Clin. Cancer Res. 9, 762–766 (2003).
  CAS PubMed Google Scholar
• De la Torre, F. J. et al. Apoptosis in epithelial ovarian tumours: prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax). Eur. J. Obstet. Gynecol. Reprod. Biol. 130, 121–128 (2007).
  Article PubMed CAS Google Scholar
• Liang, X. H. et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402, 672–676 (1999).
  Article CAS PubMed Google Scholar
• Lu, Z. et al. A novel tumor suppressor gene ARHI induces autophagy and tumor dormancy in ovarian cancer xenografts. J. Clin. Invest. 118, 3917–3929 (2008). The initial report that linked autophagy and tumour dormancy.
  CAS PubMed PubMed Central Google Scholar
• Ren, J. et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res. 15, 3006–3014 (2006).
  Article CAS Google Scholar
• Fishman, D. A. et al. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 1, 3194–3199 (2001).
  Google Scholar
• Fang, X. et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J. Biol. Chem. 279, 9653–9661 (2004).
  Article CAS PubMed Google Scholar
• Sood A, K. et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin. Cancer Res. 15, 369–375 (2006). This report links stress to ovarian cancer growth through physiological mechanisms.
  Article CAS Google Scholar
• Barbolina, M. V. et al. Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J. Biol. Chem. 16, 4924–4931 (2007).
  Article CAS Google Scholar
• Cai, K. Q. et al. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol. Carcinog. 46, 130–143 (2007).
  Article CAS PubMed Google Scholar
• Prezas, P. et al. Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol. Chem. 387, 807–811 (2006).
  CAS PubMed Google Scholar
• Paliouras, M. et al. Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 28, 61–79 (2007).
  Article CAS Google Scholar
• Yin, B. W. T. & Lloyd, K. O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem. 276, 27371–27375 (2001).
  Article CAS PubMed Google Scholar
• Gubbels, J. A. et al. Mesothelin–MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer 5, 50 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Rump, A., Morikawa, Y. & Tanaka, M. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 279, 9190–9198 (2004).
  Article CAS PubMed Google Scholar
• Cannistra, S. A. et al. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J. Clin. Oncol. 13, 1912–1921 (1995).
  Article CAS PubMed Google Scholar
• Strobel, T., Swanson, L. & Cannistra, S. A. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res. 57, 1228–1232 (1997).
  CAS PubMed Google Scholar
• Yoneda, J. et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl Cancer Inst. 90, 447–454 (1998).
  Article CAS PubMed Google Scholar
• Birrer, M. J. et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J. Clin Oncol. 1, 2281–2287 (2007). A recent comparative genomic hybridization analysis that indicates the importance of FGF1 in the pathogenesis of ovarian cancer.
  Article CAS Google Scholar
• Monk, B. J. et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 102, 140–144 (2006).
  Article CAS PubMed Google Scholar
• Kamat, A. A. et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 67, 281–288 (2007).
  Article CAS PubMed Google Scholar
• Lu, C. et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am. J. Obstet. Gynecol. 198, 477.e1–477.e9 (2008).
  Article CAS Google Scholar
• Lin, Y. G. et al. EphA2 overexpression in associated with angiogenesis in ovarian cancer. Cancer 109, 332–340 (2007).
  Article CAS PubMed Google Scholar
• Landen, C. N. et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J. Natl Cancer Inst. 98, 1558–1570 (2006).
  Article CAS PubMed Google Scholar
• Landen, C. N. et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol. Ther. 5, 1708–1713 (2006). This paper showed that neutral liposomes allow the efficient delivery of siRNA to human ovarian cancer xenografts.
  Article CAS PubMed Google Scholar
• Mancuso, M. R. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610–2621 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, G. et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl Acad. Sci. USA 31, 16472–16477 (2006).
  Article CAS Google Scholar
• Milliken, D. et al. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer Res. 8, 1108–1114 (2002).
  CAS PubMed Google Scholar
• Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 16, 203–213 (2003). A thorough study that documents the prognostic significance of T cell infiltration in ovarian cancer.
  Article Google Scholar
• Sato, E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102, 18538–18543 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Jiang, Y. P. et al. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol. Oncol. 103, 226–233 (2006).
  Article CAS PubMed Google Scholar
• Kryczek, I. et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65, 465–472 (2005).
  CAS PubMed Google Scholar
• Curiel, T. J. et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64, 5535–5538 (2004).
  Article CAS PubMed Google Scholar
• Kajiyana, H. et al. Involvement of SDF-1α/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian cancer. Int. J. Cancer 122, 91–99 (2008).
  Article CAS Google Scholar
• Szosarek, P. W. et al. Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium. Mol. Cancer Ther. 5, 382–390 (2006).
  Article Google Scholar
• Kulbe, H. et al. The inflammatory cytokine tumor necrosis factor-α generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 67, 585–592 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Madhusdan, S. et al. Study of etanercept, a tumor necrosis α inhibitor, in recurrent ovarian cancer. J. Clin. Oncol. 23, 5950–5959 (2005).
  Article CAS Google Scholar
• Rustin, G. J. S. et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin. Cancer Res. 10, 3919–3926 (2004). A recent review regarding the application of CA125 to clinical trials.
  Article CAS PubMed Google Scholar
• Menon, U. et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10, 327–340 (2009). Initial data from this trial suggest that combining CA125 and transvaginal ultrasound will be an effective strategy for the early detection of ovarian cancer.
  Article PubMed Google Scholar
• Das, P. M. & Bast, R. C Jr. Early detection of ovarian cancer. Biomarkers Med. 2, 291–303 (2008).
  Article CAS Google Scholar
• Bouchard, D. et al. Proteins with whey-acidic protein motifs and cancer. Lancet Oncol. 7, 167–174 (2006).
  Article CAS PubMed Google Scholar
• Lu, K. H. et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10, 3291–3300 (2004).
  Article CAS PubMed Google Scholar
• Clarke, C. H. et al. A panel of proteomic markers improves the sensitivity of CA125 for detecting stage I epithelial ovarian cancer. J. Clin. Oncol. 26 (Suppl.) 5542 (2008).
  Article Google Scholar
• Bast, R. C. et al. Optimizing a two-stage strategy for early detection of ovarian cancer. NCI Translational Science Meeting 300, #292. National Cancer Institute [online] (2008).
• Shridhar, V., et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 61, 5895–5904 (2001).
  CAS PubMed Google Scholar
• Marquez, R. T. et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium and colon. Clin. Cancer Res. 11, 6116 (2005). This study showed that the gene expression profiles of different ovarian cancer histotypes correlate with their morphological counterparts in normal tissues.
  Article CAS PubMed Google Scholar
• Cheng, W. et al. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nature Med. 11, 531 (2005). The authors make a convincing argument that the HOX genes have a role in determining ovarian cancer histotypes.
  Article CAS PubMed Google Scholar
• Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198–5208 (2008).
  Article CAS PubMed Google Scholar
• Schwartz, D. R. et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 63, 4722–4729 (2002).
  Google Scholar
• Kurman R. J. & Shih, L. E. M. Pathogenesis of ovarian cancer: lessons from morphology and biology and their clinical implications. Int. J. Gynecol. Pathol. 27, 151–160 (2008). This review summarizes the evidence for type I and type II ovarian cancer.
  Google Scholar
• Bast, R. C. Jr et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl. J. Med. 309, 883–887 (1983). This is the original report of the CA125 assay.
  Article PubMed Google Scholar
• Spaeth, E. L. et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contribures to fibrovascular network expansion and tumor progression. PLoS ONE 4, e4992 (2009).
  Article PubMed PubMed Central CAS Google Scholar